Dr. Kelsey A. Klute

Oncology
Emile 42nd St, 
Omaha, NE 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Emile 42nd St, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kelsey Klute is an Oncologist in Omaha, Nebraska. Dr. Klute is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Familial Colorectal Cancer. Dr. Klute is currently accepting new patients.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NE
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
Enrollment Status: Recruiting
Publish Date: April 01, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Paclitaxel, Ramucirumab, Trifluridine, Tipiracil Hydrochloride
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Ivosidenib, Pemigatinib
Study Phase: Phase 1
A Prospective, Multi-Center Investigational Study of Heart Rate Variability Monitoring for the Early Detection of Pancreatic Cancer
A Prospective, Multi-Center Investigational Study of Heart Rate Variability Monitoring for the Early Detection of Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: November 22, 2022
Intervention Type: Other, Device
View 9 Less Clinical Trials

43 Total Publications

Mechanistic Insights Driving Translational Progress in Pancreatic Cancer.
Mechanistic Insights Driving Translational Progress in Pancreatic Cancer.
Journal: Cellular and molecular gastroenterology and hepatology
Published: November 10, 2025
Similar Doctors
Experienced in DICER1 Syndrome
Dr. Margaret B. Block
Hematology Oncology | Oncology | Hematology
Experienced in DICER1 Syndrome
Dr. Margaret B. Block
Hematology Oncology | Oncology | Hematology

Oncology Hematology West, PC

8303 Dodge St, Suite 250, 
Omaha, NE 
 (3.4 miles away)
402-354-8124
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Margaret Block is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Block is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Inflammatory Breast Cancer. Dr. Block is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Mary H. Wells
Hematology Oncology | Hematology | Oncology
Experienced in DICER1 Syndrome
Dr. Mary H. Wells
Hematology Oncology | Hematology | Oncology

Oncology Hematology West, PC

8303 Dodge St, Suite 250, 
Omaha, NE 
 (3.4 miles away)
402-354-8124
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mary Wells is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Wells has been practicing medicine for over 10 years and is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Wells is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Niyati J. Nadkarni
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in DICER1 Syndrome
Dr. Niyati J. Nadkarni
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Nebraska Methodist Hospital

717 N 190th Plaza, Suite 2400, 
Elkhorn, NE 
 (12.3 miles away)
402-815-1901
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Niyati Nadkarni is a Gynecologic Oncologist and an Oncologist in Elkhorn, Nebraska. Dr. Nadkarni is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Hysterectomy. Dr. Nadkarni is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klute's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile